Deep Track Capital LP acquired a new position in shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 13,998,491 shares of the biotechnology company's stock, valued at approximately $34,436,000. Agenus comprises approximately 2.2% of Deep Track Capital LP's investment portfolio, making the stock its 17th largest position. Deep Track Capital LP owned about 5.18% of Agenus at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. U.S. Capital Wealth Advisors LLC acquired a new stake in Agenus during the 1st quarter worth $25,000. Bank of Nova Scotia purchased a new stake in shares of Agenus in the first quarter valued at about $31,000. Covestor Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Acadian Asset Management LLC purchased a new stake in shares of Agenus in the fourth quarter valued at about $32,000. Finally, Qube Research & Technologies Ltd purchased a new stake in shares of Agenus in the fourth quarter valued at about $40,000. 51.89% of the stock is owned by hedge funds and other institutional investors.
Get Agenus alerts:Wall Street Analysts Forecast Growth
Separately, TheStreet downgraded shares of Agenus from a "c-" rating to a "d" rating in a report on Friday, May 27th.
Agenus Stock Performance
Shares of AGEN stock opened at $2.69 on Friday. Agenus Inc. has a one year low of $1.25 and a one year high of $6.64. The company has a 50 day moving average price of $2.70 and a 200 day moving average price of $2.32. The firm has a market capitalization of $761.70 million, a price-to-earnings ratio of 26.90 and a beta of 1.17.Agenus (NASDAQ:AGEN – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. Agenus had a net margin of 3.07% and a return on equity of 11.65%. During the same quarter in the prior year, the business posted ($0.37) EPS. As a group, equities analysts forecast that Agenus Inc. will post -0.7 EPS for the current fiscal year.
About Agenus
(Get Rating)
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Further Reading
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN – Get Rating).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.